Cellule staminali: dal laboratorio alla clinica - Comtecmed.com
Cellule staminali: dal laboratorio alla clinica - Comtecmed.com
Cellule staminali: dal laboratorio alla clinica - Comtecmed.com
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Anti‐CD19 BiTE Blinatumomab Induces High Complete<br />
Remission Rate In Adult Patients with Relapsed B‐Precursor<br />
ALL: Updated Results of An Ongoing Phase II Trial<br />
Max S. Topp, Wuerzburg University Medical Center, Germany<br />
Abs #252<br />
N. treated patients: 18<br />
Adverse events: pyrexia and chills, CNS SAE in 4 (1 treatment<br />
withdrawal and 3 temporary interruption). 1 patient treated with<br />
initial dose of 15g/m²/day had a DIC)/cytokine release syndrome<br />
(CRS) with treatment drop‐off. No BiTE related deaths.<br />
Response rate: CR: 12/18 (67%), all MRD‐, including 3 t(4;11) and 1<br />
Ph+<br />
4 HSCT, 2 REL (1 CD19‐), 6 CCR<br />
Conclusions: BiTE induces an unprecedented high rate of<br />
<strong>com</strong>plete hematological and MRD responses in adult<br />
patients with relapsed/refractory B‐precursor ALL.
Change language